ERBB2 and mucinous ovarian cancer: Briefly, mutations in KRAS (55%), CDKN2A (55%, including deletions), TP53 (52%), ARID1A (10%), BRAF (8%), and amplification of HER2 (28%) are the most frequent abnormalities observed in primary mucinous ovarian cancer [13,17,18,19,20,21,22].